CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02178241
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:28.884348+00:00
Published At: 2019-12-16T00:00:00+00:00
Record Updated At: 2019-12-16
Results Posted At: 2019-12-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Ureter Carcinoma", "Metastatic Urethral Carcinoma", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Ureter Cancer AJCC v7", "Stage III Urethral Cancer AJCC v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7", "Stage IV Ureter Cancer AJCC v7", "Stage IV Urethral Cancer AJCC v7", "Ureter Urothelial Carcinoma", "Urethral Urothelial Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-12-16"
protocolSection.identificationModule.nctId: "NCT02178241"
protocolSection.identificationModule.officialTitle: "Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-12-16"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.